Stay updated on AstraZeneca PLC ADR Press Releases

Sign up to get notified when there's something new on the AstraZeneca PLC ADR Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the AstraZeneca PLC ADR Press Releases page

  1. Check
    9 days ago
    Change Detected
    Summary
    New press release headlines with dates have been added to the page, highlighting recent corporate activity, regulatory progress, and product news. Older press release entries have been removed from the listing.
    Difference
    5%
    Check dated 2026-09-29T22:56:52.000Z thumbnail image
  2. Check
    16 days ago
    Change Detected
    Summary
    Three new press releases were added highlighting EU CHMP recommendations and US Priority Review for multiple therapies (including Klygefa for generalised myasthenia gravis, Enhertu in the EU, and Efzimfotase alfa in the US, dated 18 September 2026). Four older items were removed from the archive: the Zegfrovy lung cancer license, Tagrisso plus Orpathys PFS results, Tezspire eosinophilic esophagitis results, and an entry dated 27 August 2026.
    Difference
    5%
    Check dated 2026-09-22T23:10:43.000Z thumbnail image
  3. Check
    23 days ago
    Change Detected
    Summary
    New entries were added to the press releases list, including DESTINY-Lung04 and ADAURA Phase III updates with dates, as well as SERENA-4 updates. Some older trial-result entries were removed from the list.
    Difference
    5%
    Check dated 2026-09-15T21:48:03.000Z thumbnail image
  4. Check
    30 days ago
    Change Detected
    Summary
    New press release entries were added to the page, including updates on Imfinzi plus Imdelltra and other 2026 announcements, expanding the latest communications. Several older items were removed from the list, reshaping the press release archive to reflect current communications.
    Difference
    5%
    Check dated 2026-09-08T18:17:48.000Z thumbnail image
  5. Check
    51 days ago
    Change Detected
    Summary
    New press release entries were added to the Media Centre, including DESTINY-Lung04 phase III results for Enhertu in HER2-mutant NSCLC, an update on the eVOLVE-Lung02 trial, and results for Tagrisso plus Orpathys in MET-driven EGFR-mutated lung cancer, with the date 17 August 2026 noted. The list also removed several older items, including the Zegfrovy licensing agreement for lung cancer, the CARDIO-TTRansform update for Wainua, and Enhertu EU tumor-agnostic approval.
    Difference
    5%
    Check dated 2026-08-18T16:02:37.000Z thumbnail image
  6. Check
    65 days ago
    Change Detected
    Summary
    A new press release entry dated 31 July 2026 about Datroway's EU approval and overall survival benefit for first-line metastatic TNBC was added to the press releases list. An older entry from 28 June 2026 about Efzimfotase alfa in pediatric hypophosphatasia was removed.
    Difference
    0.9%
    Check dated 2026-08-04T09:35:56.000Z thumbnail image

Stay in the know with updates to AstraZeneca PLC ADR Press Releases

Enter your email address, and we'll notify you when there's something new on the AstraZeneca PLC ADR Press Releases page.